A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors

被引：0
|
作者：
Saura, Cristina
Jones, Suzanne
Mateo, Joaquin
Hollebecque, Antoine
Cleary, James M.
Perez, Desamparados Roda
Zhu, Jin
Musib, Luna C.
Patel, Premal H.
Cervantes-Ruiperez, Andres
Isakoff, Steven J.
Soria, Jean-Charles
Molife, L. Rhoda
Tabernero, Josep
Bendell, Johanna C.
机构：
[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Royal Marsden Hosp, Surrey, England
[4] Inst Canc Res, Surrey, England
[5] Inst Gustave Roussy, Villejuif, France
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Hosp Clin, Dept Med Oncol, Colorectal Unit, Dept Surg, Valencia, Spain
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] Univ Valencia, Dept Hematol & Med Oncol, INCLIVA, Valencia, Spain
[10] Massachusetts Gen Hosp, Boston, MA 02114 USA
[11] Sarah Cannon Res Inst Tennessee Oncol PLLC, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3021
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR GDC-0068 WITH DOCETAXEL (D) OR MODIFIED FOLFOX6 (F) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
    Bendell, J.
    Roda, D.
    Mateo, J.
    Hollebecque, A.
    De Mattos-Arruda, L.
    Meng, R.
    Isakoff, S.
    Molife, L. R.
    Tabernero, J.
    Cervantes Ruiperez, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
  • [2] PI3K/AKT ACTIVATION AND RESPONSE IN PHASE IB: AKT INHIBITOR GDC-0068 WITH DOCETAXEL (D) OR MFOLFOX6 (F) IN REFRACTORY SOLID TUMORS
    Meng, R.
    Molife, L. R.
    de Mattos-Arruda, L.
    Hollebecque, A.
    Isakoff, S. J.
    Roda, D.
    Yan, Y.
    Cervantes, A.
    Soria, J. C.
    Mateo, J.
    Argiles, G.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2013, 24 : 33 - 33
  • [3] Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors
    Bendell, Johanna C.
    LoRusso, Patricia
    Cho, Daniel C.
    Musib, Luna
    Yan, Yibing
    Chang, Ilsung
    Patel, Premal
    Chang, Iris T.
    Meng, Raymond D.
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2014, 74 (19)
  • [4] Results of the First-in-human Phase I Study of GDC-0068, an Akt Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in Patients (pts) with Advanced Solid Tumors
    Cervantes, A.
    Saura, C.
    Roda, D.
    Dienstmann, R.
    Rosello, S.
    Carles, J.
    Funke, R.
    Zhu, J.
    Meng, R.
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 191 - 191
  • [5] A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
    Geoffrey I. Shapiro
    Patricia LoRusso
    Daniel C. Cho
    Luna Musib
    Yibing Yan
    Matthew Wongchenko
    Ilsung Chang
    Premal Patel
    Iris T. Chan
    Sandra Sanabria-Bohorquez
    Raymond D. Meng
    Johanna C. Bendell
    Investigational New Drugs, 2021, 39 : 163 - 174
  • [6] A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Cho, Daniel C.
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Chang, Ilsung
    Patel, Premal
    Chan, Iris T.
    Sanabria-Bohorquez, Sandra
    Meng, Raymond D.
    Bendell, Johanna C.
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 163 - 174
  • [7] JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Alsina, Maria
    Weinberg, Zev A.
    Chau, Ian
    Zhu, Jin
    Chan, Wai Y.
    Patel, Premal H.
    Meng, Raymond D.
    Ajanl, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] PHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR IPATASERTIB (IPAT) WITH PACLITAXEL (P) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
    Isakoff, S. J.
    Infante, J. R.
    Juric, D.
    Chan, W. Y.
    Jia, S.
    Musib, L.
    Zhu, J.
    Meng, R.
    Patel, P. H.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [9] A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors.
    Kitzen, J
    Attard, G
    de Jonge, M
    Reid, A
    Verweij, J
    Pronk, L
    Zhi, JG
    Fong, P
    Zugmaier, G
    De Bono, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9060S - 9060S
  • [10] Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6+bevacizumab in patients with advanced solid tumors and colorectal cancer
    Roseri, L.
    Goldman, J.
    Hubbard, J. M.
    Roos, M.
    Capdevila, J.
    Maynes, J.
    Lin, W.
    O'Keeffe, B.
    Lackner, M.
    Spoerke, J.
    Ware, J.
    Arnieri, B.
    Freas, E.
    Leong, S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 122 - 123
12345